Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
Primary Purpose
Glaucoma
Status
Unknown status
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Glafkos drainage device
Sponsored by
About this trial
This is an interventional prevention trial for Glaucoma
Eligibility Criteria
Inclusion Criteria:
- Patient must be 18 years of age or older.
- Patient shall suffer from primary open angle glaucoma, pseudo-exfoliative glaucoma, or refractory glaucoma after failed previous filtering surgery, in the study eye. Diagnosis is based on glaucomatous optic neuropathy, Shaffer angle greater than 2 as seen on gonioscopy, and visual field defect attributed to glaucoma.
- Eye to be treated shall be phakic or pseudophakic with no other active ocular disease or disorder except for incipiens cataract. Prior ophthalmic surgery in the study eye shall have been performed more than 3 months before enrollment in this study.
- Patient condition is indicated for primary and secondary filtration surgery.
- Presence of ocular hypertension defined as an intraocular corrected pressure (IOP) > 20 mmHg in the study eye, under maximally tolerated medications. The IOP level shall be obtained on 2 consecutive measurements (not taken on the same day) prior to surgery.
- Distance Snellen best corrected visual acuity (BCVA) better than 0.6 in the fellow eye.
- For the first three subjects the Snellen BCVA in the study eye should be 0.5 or less. In addition, the visual field defined by the Mean Defect (MD) shall be higher than 10 dB.
- Optic neuropathy is exclusively attributed to glaucoma.
- Patient agreed to sign the written inform consent prior to entering into the investigation.
- Patient is able and willing to complete post-operative follow-up requirements.
Exclusion Criteria:
- Diagnosis of neovascular glaucoma, congenital glaucoma.
- History of previous intraocular surgery in the study eye referring to but not limited to extraocular muscles (strabismus), corneal transplant, retinal surgery.
- Proliferative or severe non-proliferative retinopathy in either eye.
- Congenital anomaly of the anterior chamber angle in the study eye.
- Optic neuropathy other than glaucoma in the study eye.
- Patient with retinal vein occlusion in the study eye.
- Patient with retinal artery occlusion in the study eye.
- Patient with corneal opacifications or irregularities that may interfere with the optic nerve evaluation or the IOP measurements in the study eye.
- Patient with a history of severe eye trauma in the study eye.
- Patient with ocular malformations such as microphthalmia in the study eye.
- Patient with concurrent inflammatory/infective eye disorder in the study eye.
- Patient with any sign of past or present uveitis (anterior/posterior).
- Patient with severe systemic disease or disabling conditions such as chronic renal failure, post organ transplants.
- Patient participating in another clinical trial or having participated in another clinical trial less than 3 months prior to entering into the investigation.
- Patient is pregnant, breast-feeding or unable to make the decision to participate in a clinical investigation (e.g. mentally ill person, mentally handicapped person)
Sites / Locations
- Montchoisi ClinicRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Glafkos device
Arm Description
Outcomes
Primary Outcome Measures
Number and type of SADE per patient.
IOP measurement
IOP reduced by ≥ 20% or IOP < 21 mmHg, and no IOP < 5 mmHg on two consecutive visits after 3 months.
Secondary Outcome Measures
Comprehensive biomicroscopy examination
Anterior and posterior segments examination using a slit-lamp biomicroscope to evaluate the condition of the cornea (epithelium, stroma, endothelium), the anterior chamber, the iris, the lens, the irido-corneal angle (cf. gonioscopy outcome 9), the vitreous body, retinal and optic nerve anatomy (cf funduscopy outcome 7).
Assessment of easiness of surgery by surgeon
scale: 0=very easy to 5=very difficult
Assessment of easiness of adjustment
scale: 0=very easy to 5=very difficult
Subjective refraction
Assessment of the subjective refraction based on trial and error asking using trial lenses to achieve the best corrected visual acuity
Funduscopy evaluation
indirect funduscopy using a 90D lens to evaluate the optic nerve anatomy (cup to disk ratio measurement) and the retinal structures
Snellen BCVA
Distance (6m) decimal visual acuity after best optical correction was provided
gonioscopy assessment
Irido-corneal angle assessment using the Schaffer grading scale (1-4)
Full Information
NCT ID
NCT02554214
First Posted
September 10, 2015
Last Updated
September 17, 2015
Sponsor
Rheon Medical SA
1. Study Identification
Unique Protocol Identification Number
NCT02554214
Brief Title
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
Study Type
Interventional
2. Study Status
Record Verification Date
September 2015
Overall Recruitment Status
Unknown status
Study Start Date
September 2015 (undefined)
Primary Completion Date
September 2017 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rheon Medical SA
4. Oversight
5. Study Description
Brief Summary
This will be a prospective, descriptive, mono-center, non-comparative study. A sample of 30 patients who satisfy entry criteria is estimated to be appropriate to provide safety and performance data for this study.
The objectives of the study are to verify the performance and safety of the Glafkos adjustable glaucoma drainage device system. Performance will be measured assessing the possibility to adjust the intra-ocular pressure post-operatively. Safety will be measured by the incidence and severity of adverse events.
The Glafkos device will be implanted in combination with a seton tube. The implant is placed under a scleral flap, in a manner analogous to the ex-Press device (Alcon). The distal end of the draining tube is linked to a seton draining tube, which is linked to a plate placed under the extraocular muscles, creating a filtering space at the orbit (filtering bleb).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glaucoma
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Glafkos device
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Glafkos drainage device
Other Intervention Name(s)
eyeWatch
Primary Outcome Measure Information:
Title
Number and type of SADE per patient.
Time Frame
24 months
Title
IOP measurement
Description
IOP reduced by ≥ 20% or IOP < 21 mmHg, and no IOP < 5 mmHg on two consecutive visits after 3 months.
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Comprehensive biomicroscopy examination
Description
Anterior and posterior segments examination using a slit-lamp biomicroscope to evaluate the condition of the cornea (epithelium, stroma, endothelium), the anterior chamber, the iris, the lens, the irido-corneal angle (cf. gonioscopy outcome 9), the vitreous body, retinal and optic nerve anatomy (cf funduscopy outcome 7).
Time Frame
day 1, day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24
Title
Assessment of easiness of surgery by surgeon
Description
scale: 0=very easy to 5=very difficult
Time Frame
day 0
Title
Assessment of easiness of adjustment
Description
scale: 0=very easy to 5=very difficult
Time Frame
for 24 months
Title
Subjective refraction
Description
Assessment of the subjective refraction based on trial and error asking using trial lenses to achieve the best corrected visual acuity
Time Frame
day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24
Title
Funduscopy evaluation
Description
indirect funduscopy using a 90D lens to evaluate the optic nerve anatomy (cup to disk ratio measurement) and the retinal structures
Time Frame
day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24
Title
Snellen BCVA
Description
Distance (6m) decimal visual acuity after best optical correction was provided
Time Frame
day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24
Title
gonioscopy assessment
Description
Irido-corneal angle assessment using the Schaffer grading scale (1-4)
Time Frame
day 7 and day 28
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient must be 18 years of age or older.
Patient shall suffer from primary open angle glaucoma, pseudo-exfoliative glaucoma, or refractory glaucoma after failed previous filtering surgery, in the study eye. Diagnosis is based on glaucomatous optic neuropathy, Shaffer angle greater than 2 as seen on gonioscopy, and visual field defect attributed to glaucoma.
Eye to be treated shall be phakic or pseudophakic with no other active ocular disease or disorder except for incipiens cataract. Prior ophthalmic surgery in the study eye shall have been performed more than 3 months before enrollment in this study.
Patient condition is indicated for primary and secondary filtration surgery.
Presence of ocular hypertension defined as an intraocular corrected pressure (IOP) > 20 mmHg in the study eye, under maximally tolerated medications. The IOP level shall be obtained on 2 consecutive measurements (not taken on the same day) prior to surgery.
Distance Snellen best corrected visual acuity (BCVA) better than 0.6 in the fellow eye.
For the first three subjects the Snellen BCVA in the study eye should be 0.5 or less. In addition, the visual field defined by the Mean Defect (MD) shall be higher than 10 dB.
Optic neuropathy is exclusively attributed to glaucoma.
Patient agreed to sign the written inform consent prior to entering into the investigation.
Patient is able and willing to complete post-operative follow-up requirements.
Exclusion Criteria:
Diagnosis of neovascular glaucoma, congenital glaucoma.
History of previous intraocular surgery in the study eye referring to but not limited to extraocular muscles (strabismus), corneal transplant, retinal surgery.
Proliferative or severe non-proliferative retinopathy in either eye.
Congenital anomaly of the anterior chamber angle in the study eye.
Optic neuropathy other than glaucoma in the study eye.
Patient with retinal vein occlusion in the study eye.
Patient with retinal artery occlusion in the study eye.
Patient with corneal opacifications or irregularities that may interfere with the optic nerve evaluation or the IOP measurements in the study eye.
Patient with a history of severe eye trauma in the study eye.
Patient with ocular malformations such as microphthalmia in the study eye.
Patient with concurrent inflammatory/infective eye disorder in the study eye.
Patient with any sign of past or present uveitis (anterior/posterior).
Patient with severe systemic disease or disabling conditions such as chronic renal failure, post organ transplants.
Patient participating in another clinical trial or having participated in another clinical trial less than 3 months prior to entering into the investigation.
Patient is pregnant, breast-feeding or unable to make the decision to participate in a clinical investigation (e.g. mentally ill person, mentally handicapped person)
Facility Information:
Facility Name
Montchoisi Clinic
City
Lausanne
State/Province
Vaud
ZIP/Postal Code
1006
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
André Mermoud, Prof.
Phone
+4121 619 37 42
Email
amermoud@gsvn.ch
First Name & Middle Initial & Last Name & Degree
André Mermoud, Prof. MD.
First Name & Middle Initial & Last Name & Degree
Sylvain Roy, Dr. MD.
12. IPD Sharing Statement
Learn more about this trial
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
We'll reach out to this number within 24 hrs